ATE326231T1 - Mutierendes enterotoxin als nichttoxisches orales adjuvans - Google Patents

Mutierendes enterotoxin als nichttoxisches orales adjuvans

Info

Publication number
ATE326231T1
ATE326231T1 AT95928662T AT95928662T ATE326231T1 AT E326231 T1 ATE326231 T1 AT E326231T1 AT 95928662 T AT95928662 T AT 95928662T AT 95928662 T AT95928662 T AT 95928662T AT E326231 T1 ATE326231 T1 AT E326231T1
Authority
AT
Austria
Prior art keywords
enterotoxin
mutating
oral adjuvant
toxic oral
antigen
Prior art date
Application number
AT95928662T
Other languages
English (en)
Inventor
John D Clements
Bonny L Dickinson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE326231T1 publication Critical patent/ATE326231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT95928662T 1994-08-26 1995-07-18 Mutierendes enterotoxin als nichttoxisches orales adjuvans ATE326231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant

Publications (1)

Publication Number Publication Date
ATE326231T1 true ATE326231T1 (de) 2006-06-15

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928662T ATE326231T1 (de) 1994-08-26 1995-07-18 Mutierendes enterotoxin als nichttoxisches orales adjuvans

Country Status (22)

Country Link
US (2) US6019982A (de)
EP (1) EP0777490B1 (de)
JP (1) JP3860208B2 (de)
KR (1) KR100399258B1 (de)
CN (1) CN1182868C (de)
AT (1) ATE326231T1 (de)
AU (1) AU709779B2 (de)
BR (1) BR9508633A (de)
CA (1) CA2198586C (de)
CZ (1) CZ298131B6 (de)
DE (1) DE69534992T2 (de)
DK (1) DK0777490T3 (de)
ES (1) ES2265148T3 (de)
FI (1) FI120137B (de)
HU (1) HU222985B1 (de)
NO (1) NO317942B1 (de)
NZ (1) NZ291262A (de)
PL (1) PL182667B1 (de)
PT (1) PT777490E (de)
RU (1) RU2160606C2 (de)
WO (1) WO1996006627A1 (de)
ZA (1) ZA956412B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP0967279B1 (de) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
WO1995009649A1 (en) 1993-10-05 1995-04-13 Medeva Holdings B.V. Vaccine compositions
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
DE69529219T2 (de) * 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
EP1195162B1 (de) * 1999-03-03 2008-06-04 The Kitasato Institute Impfstoff-präparation die eine fettsäure als inhaltstoff enthält
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
AU5762299A (en) * 1999-09-15 2001-04-17 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
WO2001035993A2 (en) * 1999-10-18 2001-05-25 Chiron Corporation Compositions and methods for stimulating an immune response against infectious agents
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
AU2001280208A1 (en) 2000-08-31 2002-03-13 The Kitasato Institute Vaccine preparation containing fatty acid as component
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
CA2441530A1 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
BR0314088A (pt) * 2002-08-27 2005-07-19 Dow Agrosciences Llc Uso de toxina de escherichia coli lábil ao calor como um adjuvante em pássaros e aves domésticas
AU2003278496A1 (en) * 2002-11-14 2004-06-03 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
US20040171565A1 (en) * 2003-02-14 2004-09-02 David Hone DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
EP2272532B1 (de) 2003-09-02 2016-02-10 GlaxoSmithKline Biologicals S.A. Impfstoff gegen das Rotavirus
RU2250780C9 (ru) * 2003-11-17 2005-12-10 ГНУ Научно-исследовательский институт пушного звероводства и кролиководства им. В.А. Афанасьева Штамм бактерий escherichia coli № рпмб, предназначенный для защиты пушных зверей от токсикозов, вызванных энтеротоксинами кишечных бактерий
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
RU2305558C2 (ru) * 2004-12-09 2007-09-10 Михаил Петрович Костинов Способ лечения хронических заболеваний лор-органов вирусной, бактериальной и смешанной вирусно-бактериальной этиологии у вич-инфицированных детей и подростков
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
AU2006289626A1 (en) * 2005-09-09 2007-03-15 Universitat Zurich Antigens for vaccination against and detection of Mycoplasma suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
MX2009012676A (es) 2007-05-23 2010-02-12 Uab Research Foundation Neuraminidasa neumococica no toxica y sus usos.
EP2170377B1 (de) * 2007-07-18 2015-03-04 Development Center For Biotechnology Mutiertes hitzelabiles e. coli enterotoxin
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP3058954B1 (de) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogene zusammensetzungen und verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2698157C (en) 2007-09-11 2016-10-11 University Of Guelph Novel polysaccharide immunogens from clostridium difficile
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2195466T3 (da) 2007-10-01 2013-01-14 Longhorn Vaccines & Diagnostics Llc Fremgangsmåde til opbevaring af biologiske prøver
US8444994B2 (en) * 2008-07-01 2013-05-21 The Albert B. Sabin Vaccine Institute Multivalent antihelminthic vaccine
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
CN102712680B (zh) 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US10098940B2 (en) 2014-06-20 2018-10-16 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374379A4 (de) 2015-11-09 2019-05-15 The University Of British Columbia N-terminale epitope in amyloid-beta und konformationsselektive antikörper dagegen
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
WO2022087122A1 (en) 2020-10-20 2022-04-28 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
EP4699617A1 (de) 2024-08-22 2026-02-25 Scandinavian Biopharma Holding AB Oraler impfstoff gegen multiple diarrhöe-verursachende krankheitserreger

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung

Also Published As

Publication number Publication date
CZ298131B6 (cs) 2007-07-04
AU709779B2 (en) 1999-09-09
BR9508633A (pt) 1997-09-30
JP3860208B2 (ja) 2006-12-20
CN1182868C (zh) 2005-01-05
NO970993L (no) 1997-04-25
DE69534992D1 (de) 2006-06-22
FI120137B (fi) 2009-07-15
CN1164191A (zh) 1997-11-05
PL182667B1 (pl) 2002-02-28
JPH10505059A (ja) 1998-05-19
US6019982A (en) 2000-02-01
HUT77869A (hu) 1998-09-28
CA2198586A1 (en) 1996-03-07
ZA956412B (en) 1996-03-11
EP0777490B1 (de) 2006-05-17
KR970705403A (ko) 1997-10-09
MX9701445A (es) 1998-05-31
PT777490E (pt) 2006-10-31
RU2160606C2 (ru) 2000-12-20
PL318930A1 (en) 1997-07-21
EP0777490A1 (de) 1997-06-11
FI970799A0 (fi) 1997-02-26
FI970799L (fi) 1997-04-24
AU3233795A (en) 1996-03-22
KR100399258B1 (ko) 2003-12-31
CZ56297A3 (en) 1997-10-15
EP0777490A4 (de) 1998-11-18
DK0777490T3 (da) 2006-09-18
ES2265148T3 (es) 2007-02-01
US6440423B1 (en) 2002-08-27
DE69534992T2 (de) 2007-05-10
NZ291262A (en) 1999-02-25
NO317942B1 (no) 2005-01-10
HU222985B1 (hu) 2004-01-28
CA2198586C (en) 2010-10-12
WO1996006627A1 (en) 1996-03-07
NO970993D0 (no) 1997-03-04

Similar Documents

Publication Publication Date Title
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE69421939D1 (de) Nichttoxisches schleimhautadjuvans
EP0528859A4 (en) Oral vaccine comprising antigen surface-associated with red blood cells
FI920353A0 (fi) Pneumokockpolysackaridkonjugatvaccin.
DE69331901D1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DK0725653T3 (da) Vaccinepræparater
ATE62270T1 (de) Herstellung des e.coli-lt-benterotoxinunterteils.
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
EA200300557A1 (ru) Комбинированные композиции адъювантов
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
Vetkova et al. Protective effect of Pseudomonas aeruginosa polyvalent corpuscular vaccine in P. aeruginosa generalized chronic infection of mice with cyclophosphamide-induced leukopenia.
RU94042882A (ru) Препарат с иммуностимулирующей активностью
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0777490

Country of ref document: EP